# Galantamine for Cognitive Deficits in Schizophrenia

> **NCT00463879** · PHASE2,PHASE3 · COMPLETED · sponsor: **Yale University** · enrollment: 21 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Galantamine

## Key facts

- **NCT ID:** NCT00463879
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2007-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00463879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00463879, "Galantamine for Cognitive Deficits in Schizophrenia". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00463879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*